SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Insilico Medicine Reports 40% ORR for ISM6331 at 130 mg

Insilico Medicine reported a 40% objective response rate at 130 mg for its pan-TEAD inhibitor ISM6331 in heavily pretreated mesothelioma at ESMO 2026.

Related stories